Individualized Targeting and Neuromodulation of Late-Life Depression
Condition(s) studied
Investigational drug(s) / intervention(s)
rTMS: rTMS will be delivered to the fMRI-determined DLPFC hotspot according to conventional parameters for clinical treatment (e.g., excitatory: 75 trains of 40 pulses, 10Hz, up to 3000 pulses). Magnetic field strength will be up to 120% of resting motor threshold. Ramp up of magnetic field strength may be utilized in the first week for tolerability. Side effects will be monitored and coil angle adjusted to improve tolerability if necessary.
Study summary
An open-label, single-arm, clinical research study about how to make transcranial magnetic stimulation (TMS), an FDA-approved treatment, more effective for patients with late-life depression using fMRI.
Eligibility
Primary outcome measure(s)
- Anterior Cingulate Cortex (ACC) Connectivity — Week 3 post-treatment assessment
Change in baseline correlation index of the ACC network on resting state fMRI
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| University of New Mexico HSC | Albuquerque | New Mexico |
More University of New Mexico trials in Mexico
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04543773 on ClinicalTrials.gov ↗ ← All trials in Mexico